Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recent victories by Democratic gubernatorial candidates in New Jersey and Virginia and for seats on the Georgia Public Service Commission have led outlets like Politico to brand the outcomes as the ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
After vowing to conduct a full audit on the Democratic national political strategy because of the party’s 2024 election losses, Democratic National Committee Chairman Ken Martin says the findings of ...
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Like all other BMW models, the 5-Series is being updated as part of the carmaker’s Neue Klasse era, adopting the new styling of recent concepts and the all-electric iX3. However, it appears BMW is ...
Yahoo Sports TVyahoosports.tv is here! Watch live shows and highlights 24/7. Yahoo Sports DailyJason Fitz & Caroline Fenton bring you the top sports news to start your day. Yahoo Fantasy ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback